A combination of two types of blood pressure-lowering drugs -- an angiotensin-converting enzyme inhibitor (ACEI) plus an angiotensin-receptor blocker (ARB), added to enzyme replacement therapy (ERT) ...
A major breakthrough to change the lives of cystic fibrosis sufferers. The trial looked at the treatment of patients with two copies of the F508DEL mutation which is carried by roughly half of all ...
Ingelheim, Germany, 3rd September, 2012 – New phase II data presented for the first time today at the 2012 European Respiratory Society (ERS) congress show that combining tiotropium with olodaterol ...
Further tiotropium + olodaterol FDC data on patient outcomes such as quality of life are due to report later this year SAN DIEGO--(BUSINESS WIRE)--For media outside of the US, the UK & Canada only ...
New research has demonstrated that a combined regimen of growth hormone and testosterone is safe, well-tolerated, and is associated with meaningful improvements in muscle mass, strength, and mobility ...
Boehringer Ingelheim announced results from the Phase 3 VIVACITO study evaluating the effect of the fixed-dose combination of tiotropium and olodaterol (T + O FDC) delivered via the Respimat inhaler, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback